Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Short Interest Update

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 208 shares, a decrease of 83.6% from the August 31st total of 1,269 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 43,916 shares, the short-interest ratio is presently 0.0 days.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

OACC traded down $0.01 on Friday, hitting $10.77. The company had a trading volume of 832 shares, compared to its average volume of 32,798. The stock has a fifty day simple moving average of $10.76 and a 200-day simple moving average of $10.70. Oaktree Acquisition Corp. III Life Sciences has a 52-week low of $10.45 and a 52-week high of $10.88.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

Several large investors have recently made changes to their positions in OACC. Rangeley Capital LLC increased its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after acquiring an additional 21,156 shares in the last quarter. DLD Asset Management LP lifted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% in the first quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after buying an additional 1,200 shares in the last quarter. Lineage Point Capital LP purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter valued at approximately $2,461,000. Empyrean Capital Partners LP grew its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 20.0% during the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after buying an additional 150,000 shares during the last quarter. Finally, Radcliffe Capital Management L.P. increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 67.1% during the fourth quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock valued at $3,989,000 after acquiring an additional 151,403 shares in the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify and combine with a business in the life sciences sector. Unlike an operating company, it does not manufacture products or provide healthcare services of its own.

The company’s stated investment focus includes businesses involved in pharmaceuticals, biotechnology, medical devices, healthcare services and related life sciences technologies. Its objective is to complete a merger, stock purchase, asset acquisition, reorganization or similar business combination with a target company.

Oaktree Acquisition Corp.